ROBOSENSE
23.4.2021 20:02:05 CEST | Business Wire | Press release
During the Shanghai Auto Show, RoboSense (https://robosense.ai/ ), a smart and automotive LiDAR system provider, and Webasto (https://www.webasto-group.com/ ), the global Top 100 automotive supplier and market leader for roof systems, announced cooperation on the Smart Roof Sensor Module that integrated with RoboSense automotive-grade MEMS LiDAR RS-LiDAR-M1 for Level 3 to Level 5 autonomous driving vehicles, largely simplifying the structure and mounting process of conventional sensor sets of self-driving vehicles and ensures advanced safety perception.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005484/en/
Through this strategic cooperation, Webasto is committed to seamlessly embedding the RoboSense M1, camera and other sensor systems to the panoramic roof of vehicles to provide safer and more reliable environment perception information at the smallest possible space in the roof. The solution allows different roof systems to be mounted on the vehicle body, creating greater flexibility for the development of autonomous vehicles.
As the world’s market leader, Webasto offers the broadest product range of high-quality roof systems. The rooftop design not only enables the integration of sensor systems but also adopts highly rigid transparent material and the openable top function, which creates the feeling of freedom for the passengers.
The RoboSense M1 boasts 125 ultra-high resolution scanning beams, ultra-wide FOV of 120°*25°, and a maximum detection range of 200m (150M@10%). At present, the M1(thickness 45mm, depth 108mm, width 110mm) is the thinnest solid-state LiDAR on the market. At the highest point of the vehicle, the M1’s unique mounting position in the smart roof module gives it the vantage point of view, which can greatly improve the detection ability of the perception system and ensure the safe and stable operation of the autonomous driving systems. Moreover, it costs less fuel consumption/NEDC mileage than other LiDAR products.
“Webasto looks for the most compact and state-of-the-art perception sensing systems on the market desired by our customers for roof-mounted integration. The RoboSense M1 meets these criteria and provides both promising size and suitability for roof integration”, says Brad Tang, Strategy & Product Planning Manager at Webasto.
Mark Qiu, RoboSense Executive President and Co-Partner says, " By combining the most mature roof module technology and the most compact size MEMS solid-state LiDAR, we provide the elegant, easy-to-integrate and one-stop smart roof solution with safety perception function to OEMs and end-users.”
The SOP version of M1 has fully met the OEM’s all automotive-grade requirements.
- M1 has successfully solved point cloud’s “corner cases” including high reflectivity objects, near-field obstacles, strong ambient light (direct sunlight), and interference from other LiDAR sensors, etc.
- M1 successfully passed the automotive-grade verification tests include mechanical and vibration, shock, EMC electromagnetic compatibility, human eye safety, chemical anti-corrosion, salt spray, high and low-temperature storage and operation, etc.
- Moreover, RoboSense has established China’s first automotive-grade solid-state LiDAR production line and would start mass production and delivery in Q2 2021.
About RoboSense
Founded in 2014, RoboSense (Suteng Innovation Technology Co., Ltd.) is the leading provider of Smart LiDAR Sensor Systems incorporating LiDAR sensors, AI algorithms and IC chipsets, that transform conventional 3D LiDAR sensors to full data analysis and comprehension systems. https://robosense.ai/
About Webasto
The Webasto Group is a global innovative systems partner to almost all automobile manufacturers and among the top 100 suppliers in this industry sector. The company’s product portfolio comprises a broad range of roof and heating systems for every type of vehicle and all drive types as well as battery systems and charging solutions. http://www.webasto-group.com/ or http://www.twitter.com/WebastoGroup
View source version on businesswire.com: https://www.businesswire.com/news/home/20210423005484/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 16:44:00 CET | Press release
One SKU. Every market. Connectivity decided at the end of production. Live at electronica 2026. Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the pr
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom